I guess you are interested in Laboratorios Richmond S.A.C.I.F. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
Let's start. I'm going to help you getting a better view of Laboratorios Richmond S.A.C.I.F. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
An important factor of a company's health is the profitability.
One of the most important indicator to determine the financial health of a company is the Net Profit Margin. What is the net profit from the generated revenue? A healthy Net Profit Margin is higher than 10%.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 8.7% | 2.2% | -423.9% |
TTM | 0.9% | 1.5% | -43,400.5% |
YOY | 6.3% | 2.4% | -6,664.9% |
5Y | 1.2% | 0.6% | -11,269.3% |
10Y | 2.4% | 1.3% | -7,239.8% |
Let's take a look of the Net Profit Margin trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Net Profit Margin with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Return On Assets is above 5%.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 2.7% | 0.4% | -31.1% |
TTM | 0.5% | 0.2% | -5,075.2% |
YOY | 1.6% | 0.2% | -1,456.2% |
5Y | 0.4% | 0.1% | -1,385.0% |
10Y | 0.8% | 0.3% | -870.0% |
Let's take a look of the Return On Assets trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Return On Assets with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Return On Equity is above 15%.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 13.2% | 1.2% | -10.9% |
TTM | 2.7% | 0.8% | -20,263.5% |
YOY | 3.9% | 0.7% | -38.9% |
5Y | 1.7% | 0.3% | -3,852.7% |
10Y | 3.4% | 0.6% | -1,919.9% |
Let's take a look of the Return On Equity trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Return On Equity with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Operating Margin is above 15%.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | - | 4.9% | -326.8% |
TTM | 13.7% | 2.8% | -37,528.8% |
YOY | 21.0% | 4.1% | 8,834.9% |
5Y | 8.4% | 3.1% | -4,596.1% |
10Y | 4.7% | 2.0% | -1,187.8% |
Let's take a look of the Operating Margin trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Operating Margin with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Operating Ratio is below 1.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 1.556 | 1.382 | 3.673 |
TTM | 1.477 | 1.361 | 1,600.776 |
YOY | 1.267 | 1.373 | -87.241 |
5Y | 1.074 | 1.318 | 277.684 |
10Y | 0.809 | 1.147 | 130.843 |
Let's take a look of the Operating Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Operating Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Current Ratio is above 1.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 1.655 | 2.011 | 3.916 |
TTM | 1.382 | 2.049 | 3.587 |
YOY | 1.346 | 2.093 | 3.306 |
5Y | 0.899 | 2.121 | 5.082 |
10Y | 0.499 | 1.843 | 4.686 |
Let's take a look of the Current Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Current Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Quick Ratio is above 1.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 0.668 | 0.731 | 2.207 |
TTM | 0.523 | 0.834 | 2.206 |
YOY | 0.745 | 0.804 | 1.933 |
5Y | 0.647 | 0.835 | 1.881 |
10Y | 0.691 | 0.812 | 1.806 |
Let's take a look of the Quick Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Quick Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Total-Debt-to-Total-Assets Ratio is below 1.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 0.791 | 0.412 | 5.044 |
TTM | 0.718 | 0.411 | 5.946 |
YOY | 0.591 | 0.396 | 24.438 |
5Y | 0.649 | 0.396 | 9.475 |
10Y | 0.698 | 0.400 | 9.057 |
Let's take a look of the Total-Debt-to-Total-Assets Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Total-Debt-to-Total-Assets Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Debt-To-Equity Ratio is below 2.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 3.838 | 0.625 | 2.583 |
TTM | 3.009 | 0.660 | 2.312 |
YOY | 1.475 | 0.624 | 2.751 |
5Y | 2.148 | 0.664 | 1.949 |
10Y | 2.703 | 0.688 | 1.750 |
Let's take a look of the Debt-To-Equity Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Debt-To-Equity Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A Price-to-Earnings Ratio above 15 may indicate an overpriced stock. However this is very hard to determine. Best way is to compare the PE Ratio with the industry average.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
EOD | -182.704 | 0.410 | 0.584 |
MRQ | -170.421 | 1.141 | -3.303 |
TTM | 0.101 | 1.001 | 17.337 |
YOY | 32.273 | 3.073 | -83.308 |
5Y | 1.912 | 5.909 | -127.348 |
10Y | 1.062 | 7.016 | -147.432 |
Let's take a look of the Price-to-Earnings Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Price-to-Earnings Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
MRQ | 787.761 | 1.089 | -224.992 |
TTM | 241.981 | 0.041 | 110.620 |
YOY | -8.345 | 3.351 | 12,755.229 |
5Y | 116.818 | 7.424 | 17,111.564 |
10Y | 116.818 | 7.758 | 11,093.204 |
Let's take a look of the Price/Earnings-to-Growth Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Price/Earnings-to-Growth Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
A healthy Price-to-Book Ratio is below 3.
Period | Laboratorios Richmond S.A.C.I.F | Drug Manufacturers-Specialty & Generic (mean) | Drug Manufacturers-Specialty & Generic (average) |
---|---|---|---|
EOD | 3.575 | 1.637 | 58.918 |
MRQ | 3.335 | 1.926 | 162.075 |
TTM | 4.086 | 2.197 | 51.679 |
YOY | 3.299 | 2.274 | 299.576 |
5Y | 2.153 | 2.034 | 79.132 |
10Y | 1.196 | 1.573 | 77.620 |
Let's take a look of the Price-to-Book Ratio trends of Laboratorios Richmond S.A.C.I.F:
Let's compare the company's Price-to-Book Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:
The key performance indicators of Laboratorios Richmond S.A.C.I.F compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Per Share | - | - | 66.570 | 54.255 | +23% | 33.132 | +101% | 21.125 | +215% | 11.736 | +467% |
Current Ratio | - | - | 1.655 | 1.382 | +20% | 1.346 | +23% | 0.899 | +84% | 0.499 | +231% |
Debt To Asset Ratio | - | - | 0.791 | 0.718 | +10% | 0.591 | +34% | 0.649 | +22% | 0.698 | +13% |
Debt To Equity Ratio | - | - | 3.838 | 3.009 | +28% | 1.475 | +160% | 2.148 | +79% | 2.703 | +42% |
Eps | - | - | - | -0.326 | 0% | 1.505 | -100% | 0.308 | -100% | 0.171 | -100% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 0.950 | +5% | 0.833 | +20% |
Net Profit Margin | - | - | 0.087 | 0.009 | +821% | 0.063 | +39% | 0.012 | +608% | 0.024 | +257% |
Operating Margin | - | - | - | 0.137 | -100% | 0.210 | -100% | 0.084 | -100% | 0.047 | -100% |
Operating Ratio | - | - | 1.556 | 1.477 | +5% | 1.267 | +23% | 1.074 | +45% | 0.809 | +92% |
Pb Ratio | 3.575 | +7% | 3.335 | 4.086 | -18% | 3.299 | +1% | 2.153 | +55% | 1.196 | +179% |
Pe Ratio | -182.704 | -7% | -170.421 | 0.101 | -168964% | 32.273 | -628% | 1.912 | -9015% | 1.062 | -16146% |
Peg Ratio | - | - | 787.761 | 241.981 | +226% | -8.345 | +101% | 116.818 | +574% | 116.818 | +574% |
Price Per Share | 238.000 | +7% | 222.000 | 219.500 | +1% | 107.438 | +107% | 86.063 | +158% | 47.813 | +364% |
Quick Ratio | - | - | 0.668 | 0.523 | +28% | 0.745 | -10% | 0.647 | +3% | 0.691 | -3% |
Return On Assets | - | - | 0.027 | 0.005 | +438% | 0.016 | +71% | 0.004 | +540% | 0.008 | +246% |
Return On Equity | - | - | 0.132 | 0.027 | +389% | 0.039 | +234% | 0.017 | +687% | 0.034 | +284% |
EOD | +1 -2 | MRQ | TTM | +8 -6 | YOY | +6 -9 | 5Y | +8 -8 | 10Y | +7 -9 |
Let's check the fundamental score of Laboratorios Richmond S.A.C.I.F based on Penke's default stock scanner.
Indicator | Condition | Value | ||
---|---|---|---|---|
PE Ratio (EOD) | Between | 0-15 | -182.704 | |
PB Ratio (EOD) | Between | 0-1 | 3.575 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.087 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 0.668 | |
Current Ratio (MRQ) | Greater than | 1 | 1.655 | |
Debt Ratio (MRQ) | Less than | 1 | 0.791 | |
DE Ratio (MRQ) | Less than | 1 | 3.838 | |
ROE (MRQ) | Greater than | 0.15 | 0.132 | |
ROA (MRQ) | Greater than | 0.05 | 0.027 | |
Total | 3/10 (30.0%) |
Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner
Let's check the technical score of Laboratorios Richmond S.A.C.I.F based on Penke's default Symbol scanner.
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 49.092 | |
Ma 20 | Greater than | Ma 50 | 238.613 | |
Ma 50 | Greater than | Ma 100 | 237.075 | |
Ma 100 | Greater than | Ma 200 | 241.140 | |
Open | Greater than | Close | 235.000 | |
Total | 2/5 (40.0%) |
Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner
Balance Sheet of 2021-12-31. Currency in ARS. All numbers in thousands.
As reported | |
---|---|
Total Liabilities | 20,317,526 |
Total Stockholder Equity | + 5,293,621 |
Total Assets | = 25,693,158 |
Goodwill | 531,171 |
Intangible Assets | 1,462,932 |
Long-term Assets (as reported) | 10,258,296 |
---|---|
Long-term Assets (calculated) | 1,994,102 |
+/- | 8,264,193 |
Long term Debt | 1,187,600 |
Capital Lease Obligations Min Short Term Debt | 146,125 |
Long-term Liabilities Other | 12,302 |
Long-term Liabilities (as reported) | 10,991,342 |
---|---|
Long-term Liabilities (calculated) | 1,346,028 |
+/- | 9,645,315 |
Retained Earnings | 591,464 |
Total Stockholder Equity (as reported) | 5,293,621 |
---|---|
Total Stockholder Equity (calculated) | 591,464 |
+/- | 4,702,157 |
Common Stock Shares Outstanding | 80,751 |
Net Invested Capital | 8,269,258 |
Net Working Capital | 6,108,678 |
Currency in ARS. All numbers in thousands.
Trend | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2008-09-30 | 2007-09-30 | 2006-09-30 | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 25,693,158 | 24,167,525 | 12,165,119 | 9,254,840 | 8,133,335 | 6,986,402 | 5,845,090 | 5,260,627 | 5,134,618 | 3,807,181 | 2,948,371 | 2,805,766 | 2,705,186 | 2,402,981 | 1,821,701 | 1,637,185 | 1,552,641 | 912,391 | 779,149 | 726,253 | 861,132 | 724,917 | 640,283 | 556,555 | 532,834 | 400,815 | 391,705 | 387,299 | 385,658 | 357,608 | 323,549 | 315,091 | 287,372 | 290,686 | 276,743 | 276,743 | 270,955 | 159,025 | 135,779 | 127,840 | 107,007 | 100,634 | 77,583 | 56,356 | ||||||||||||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 15,434,862 | 10,771,693 | 7,750,533 | 5,406,240 | 5,371,511 | 4,519,380 | 3,591,461 | 3,263,874 | 3,287,659 | 2,571,194 | 1,894,278 | 1,914,169 | 1,967,306 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 4,666,788 | 1,597,793 | 404,284 | 516,623 | 493,831 | 315,168 | 500,976 | 310,788 | 217,146 | 350,686 | 258,089 | 347,465 | 501,119 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
| 2,693,158 | 85,949 | 532,356 | 347,005 | 345,707 | 357,776 | 1,085 | 1,188 | 1,720 | 3,668 | 1,148 | 799 | 481 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Net Receivables |
| 3,532,618 | 2,496,087 | 2,691,864 | 1,925,213 | 2,936,487 | 2,159,626 | 1,672,216 | 1,852,293 | 1,959,409 | 958,190 | 678,506 | 616,057 | 785,003 | 885,401 | 690,781 | 653,201 | 512,300 | 406,844 | 329,962 | 338,047 | 498,253 | 311,128 | 267,879 | 262,666 | 267,087 | 173,047 | 185,857 | 180,550 | 192,546 | 156,568 | 134,815 | 126,968 | 111,643 | 114,664 | 105,744 | 105,744 | 96,359 | 46,019 | 35,816 | 31,007 | 27,233 | 24,876 | 24,723 | 16,278 | ||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
| 0 | 372,305 | 1,191,245 | 546,618 | 287,748 | 421,935 | 248,894 | 197,338 | 178,477 | 172,835 | 124,871 | 180,388 | 150,080 | 20,857 | 32,646 | 28,038 | 12,994 | 24,376 | 12,404 | 11,873 | 14,666 | 14,311 | 9,874 | 18,756 | 4,546 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 498 | 606 | 953 | 13,310 | 16,553 | 15,252 | 888 | 918 | ||||||||||||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 10,258,296 | 13,395,832 | 4,414,586 | 3,848,600 | 3,168,386 | 2,467,021 | 2,253,630 | 1,996,753 | 1,846,959 | 1,235,987 | 1,054,093 | 891,597 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 0 | 3,046,123 | 2,725,498 | 2,337,935 | 2,015,013 | 1,429,438 | 1,347,306 | 1,250,129 | 1,196,276 | 671,096 | 569,658 | 472,937 | 383,959 | 198,977 | 96,152 | 91,649 | 91,973 | 71,867 | 70,593 | 67,184 | 58,306 | 56,996 | 55,322 | 55,560 | 55,316 | 53,642 | 54,699 | 53,702 | 54,525 | 54,516 | 0 | 52,428 | 52,549 | 0 | 0 | 0 | 52,499 | 44,800 | 37,995 | 22,918 | 22,179 | 22,083 | 20,344 | 13,126 | ||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
| 531,171 | 486,155 | 449,661 | 409,657 | 300,277 | 328,063 | 304,512 | 287,113 | 245,929 | 221,859 | 193,533 | 178,636 | 143,669 | 33,121 | 32,609 | 32,248 | 32,339 | 39,783 | 31,420 | 31,420 | 31,420 | 31,420 | 31,420 | 31,420 | 31,420 | 28,290 | 28,737 | 29,184 | 29,632 | 30,079 | 0 | 30,973 | 31,420 | 0 | 0 | 0 | 40,438 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Long Term Investments |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,218 | 5,500 | 5,355 | 4,101 | 11,692 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets |
| 1,462,932 | 1,128,651 | 975,114 | 804,240 | 623,643 | 508,649 | 421,531 | 379,915 | 335,738 | 288,322 | 240,895 | 188,206 | 3,200 | 33,913 | 32,821 | 32,376 | 32,339 | 39,783 | 31,420 | 31,420 | 31,420 | 31,420 | 31,420 | 31,420 | 31,420 | 28,771 | 28,737 | 29,184 | 29,632 | 30,079 | 6,788 | 30,973 | 31,420 | 6,174 | 5,964 | 5,964 | 40,625 | 147 | 543 | 679 | 691 | 1,622 | 457 | 311 | ||||||||||||||||||||||||||||||||||||||||||||
Long-term Assets Other |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,235,987 | 1,054,093 | 891,597 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 20,317,526 | 19,838,051 | 8,099,865 | 5,500,623 | 4,752,830 | 4,275,481 | 3,443,970 | 3,051,279 | 3,034,658 | 2,369,968 | 1,731,410 | 1,669,514 | 1,594,256 | 1,616,125 | 1,130,640 | 911,607 | 864,588 | 715,969 | 625,695 | 549,419 | 671,672 | 605,060 | 540,743 | 460,578 | 436,712 | 303,726 | 300,866 | 299,363 | 292,642 | 274,160 | 243,608 | 235,531 | 196,336 | 207,433 | 185,468 | 185,468 | 178,942 | 108,921 | 90,962 | 74,108 | 68,621 | 71,342 | 64,334 | 48,610 | ||||||||||||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 9,326,184 | 9,805,072 | 5,913,989 | 3,695,913 | 3,550,319 | 3,522,630 | 2,820,832 | 2,480,757 | 2,475,950 | 2,005,622 | 1,380,095 | 1,267,508 | 1,250,101 | 1,327,483 | 954,980 | 780,462 | 748,417 | 634,249 | 516,202 | 425,365 | 546,952 | 455,045 | 390,143 | 354,829 | 337,703 | 222,613 | 240,821 | 243,496 | 239,846 | 218,576 | 186,583 | 182,401 | 153,556 | 164,239 | 144,643 | 144,643 | 132,790 | 70,886 | 49,927 | 50,443 | 48,157 | 51,411 | 32,065 | 36,242 | ||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 346,659 | 449,337 | 340,886 | 341,545 | 302,330 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Short Long Term Debt |
| 1,788,036 | 2,090,837 | 1,871,833 | 632,373 | 659,873 | 987,993 | 566,163 | 325,998 | 346,659 | 449,337 | 340,886 | 341,545 | 302,330 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Accounts payable |
| 5,724,387 | 6,263,583 | 3,739,832 | 2,721,935 | 2,360,382 | 2,226,285 | 2,028,514 | 1,905,383 | 1,861,857 | 1,428,534 | 967,806 | 854,992 | 857,549 | 833,245 | 530,682 | 373,387 | 375,389 | 365,272 | 280,531 | 190,964 | 225,076 | 195,173 | 189,468 | 177,376 | 161,772 | 105,153 | 109,532 | 116,583 | 102,671 | 100,744 | 79,388 | 82,352 | 55,509 | 68,286 | 63,494 | 63,494 | 72,066 | 36,272 | 25,200 | 36,735 | 40,415 | 43,601 | 27,105 | 33,502 | ||||||||||||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 30,000 | 92,093 | 83,902 | 73,729 | 159,442 | 147,153 | 108,638 | 78,576 | 51,563 | 11,529 | 8,504 | 8 | 22,193 | 119,724 | 70,939 | 102,432 | 100,418 | 68,825 | 78,660 | 63,502 | 114,519 | 59,489 | 52,763 | 51,298 | 36,280 | 20,877 | 24,886 | 18,811 | 19,240 | 15,077 | 14,132 | 13,022 | 11,919 | 17,560 | 20,912 | 20,912 | 15,221 | 7,325 | 4,252 | 2,442 | 2,862 | 3,001 | 2,308 | 540 | ||||||||||||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 10,991,342 | 10,032,979 | 2,185,876 | 1,804,710 | 1,486,170 | 752,851 | 623,138 | 570,522 | 558,708 | 364,345 | 351,315 | 402,006 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 146,125 | 25,484 | 18 | 5,854 | 31,771 | 68,712 | 72,111 | 73,061 | -315,521 | -449,337 | -340,886 | -341,545 | -302,330 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Long-term Liabilities Other |
| 12,302 | 11,825 | 22,925 | 22,032 | 13,238 | 7,598 | 7,036 | 6,437 | 44,112 | 93,506 | 68,459 | 69,408 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
Deferred Long Term Liability |
| 0 | 1,120,985 | 967,297 | 796,149 | 647,600 | 501,529 | 414,059 | 372,981 | 327,755 | 282,143 | 235,836 | 183,662 | 140,103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| 5,293,621 | 4,245,571 | 3,990,315 | 3,681,875 | 3,380,506 | 2,655,308 | 2,347,810 | 2,155,494 | 2,050,207 | 1,389,902 | 1,181,850 | 1,105,404 | 1,051,302 | 709,077 | 667,279 | 708,993 | 688,053 | 196,421 | 153,454 | 176,834 | 189,460 | 119,858 | 99,540 | 95,976 | 96,121 | 97,089 | 90,839 | 87,937 | 93,016 | 83,447 | 79,941 | 79,560 | 91,036 | 83,253 | 91,274 | 91,274 | 91,953 | 50,110 | 44,815 | 53,727 | 38,381 | 29,288 | 13,245 | 7,746 | ||||||||||||||||||||||||||||||||||||||||||||
Common Stock |
| 0 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,751 | 80,752 | 80,752 | 80,752 | 80,752 | 66,584 | 66,584 | 66,584 | 27,254 | 27,254 | 27,254 | 27,254 | 27,254 | 27,254 | 27,254 | 27,254 | 27,254 | 27,254 | 66,584 | 27,254 | 27,254 | 66,584 | 66,584 | 66,584 | 27,254 | 27,254 | 27,254 | 3,642 | 3,642 | 2,822 | 2,822 | 133 | ||||||||||||||||||||||||||||||||||||||||||||
Retained Earnings |
| 591,464 | 518,403 | 545,360 | 459,822 | 494,981 | 172,675 | 36,813 | -12,206 | 6,420 | -388,342 | -368,480 | -338,266 | -71,520 | 89,372 | 83,834 | 135,917 | 115,573 | 103,289 | 86,870 | 110,250 | 122,876 | 53,273 | 32,956 | 29,392 | 29,537 | 30,504 | 24,255 | 21,352 | 26,432 | 16,863 | 13,356 | 12,975 | 24,452 | 16,669 | 24,690 | 24,690 | 25,369 | 22,856 | 17,561 | 14,519 | 12,265 | 10,966 | 10,423 | 7,429 | ||||||||||||||||||||||||||||||||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
Other Stockholders Equity |
| 0 | 1,564,253 | 1,458,905 | 1,424,085 | 1,284,478 | 1,036,270 | 961,737 | 883,139 | 846,328 | 463,986 | 373,046 | 361,582 | 316,146 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency in ARS. All numbers in thousands.
Currency in ARS. All numbers in thousands.
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 16,615,676 | |
Cost of Revenue | -11,686,598 | |
Gross Profit | 4,929,078 | 4,929,078 |
Operating Income (+$) | ||
Gross Profit | 4,929,078 | |
Operating Expense | -14,293,099 | |
Operating Income | 2,322,577 | -9,364,021 |
Operating Expense (+$) | ||
Research Development | - | |
Selling General Administrative | 951,099 | |
Selling And Marketing Expenses | - | |
Operating Expense | 14,293,099 | 951,099 |
Net Interest Income (+$) | ||
Interest Income | - | |
Interest Expense | -744,857 | |
Net Interest Income | -744,857 | -744,857 |
Pretax Income (+$) | ||
Operating Income | 2,322,577 | |
Net Interest Income | -744,857 | |
Other Non-Operating Income Expenses | - | |
Income Before Tax (EBT) | 1,417,446 | 2,322,577 EBIT - interestExpense = -744,857 591,464 1,336,321 |
Interest Expense | 744,857 | |
Earnings Before Interest and Taxes (ebit) | - | 2,162,302 |
Earnings Before Interest and Taxes (ebitda) | 2,507,899 | |
After tax Income (+$) | ||
Income Before Tax | 1,417,446 | |
Tax Provision | -816,014 | |
Net Income From Continuing Ops | 601,432 | 601,432 |
Net Income | 591,464 | |
Net Income Applicable To Common Shares | - | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | - | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | - | |
Total Other Income/Expenses Net | - | 744,857 |
Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.
Join the conversation.
I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPRUB.FOREX.
I found you a Oversold RSI (Relative Strength Index) on the daily chart of CADRUB.FOREX.
I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGDBRL.FOREX.
I found you a Oversold RSI (Relative Strength Index) on the daily chart of HKDRUB.FOREX.
I found you a Golden Cross on the daily chart of CHFCZK.FOREX.